Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Leriglitazone (Primary)
  • Indications Adrenoleucodystrophy; Adrenomyeloneuropathy
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Minoryx Therapeutics

    • Most Recent Events

    • 26 Jan 2024 According to a Minoryx Therapeutics media release, Minoryx and Neuraxpharm strongly believe that leriglitazone has a positive benefit-risk balance in patients with cALD. Result data from this study is now supported by 24 week data from NEXUS trial. Findings are being validated through confirmatory long term follow-up from ongoing trials NEXUS and CALYX, in adult patients with progressive cALD.
    • 26 Jan 2024 According to a Minoryx Therapeutics media release, companies are going to request re-examination of leriglitazone for conditional marketing authorisation for treatment of patients with cALD based on additional evidence generated from the two ongoing confirmatory trials (CALYX and NEXUS).
    • 26 Jan 2024 According to a Minoryx Therapeutics media release, company announced that the EMAs Committee for Medicinal Products for Human Use (CHMP) has recommended not to grant marketing authorization for leriglitazone as a treatment of X-ALD. Companies are seeking a re-examination for conditional approval for patients with cerebral adrenoleukodystrophy, which is characterized by demyelinating brain lesions which can become rapidly progressive, leading to acute neurological decline and death in 3-4 years.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top